Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Therapy-556 > COPD > Flashcards

COPD Flashcards

1
Q

Chronic Obstructive Pulmonary Disease (COPD)

A

-PERSISTANT respritory symptoms
-airflow limitation
-PROGRESSIVE
-exacerbations
-comorbities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

true or false: deaths resulting from COPD are higher in women than in men

A

true.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

COPD prevalence

A

-3rd leading cause of death
-affects females more than males
-affects American indians/alaskan native descendants more

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

COPD pathophysiology

A

-emphesema and chronic bronchitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is required for COPD diagnosis?

A

spirometry test
-FEV1/FVC <70% post bronchodialator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

COPD symptoms

A

-dyspnea
-chronic cough
-sputum production
-wheezing, chest tightnes
-lower respritory tract infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

COPD risk factors

A

-exposure to particles
-Socioeconomi status
-age and sex
-genes
-asthma, chronic bronchitis
-childhood lung abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Emphysema

A

-in aveoli
-destruction of lung parenchyma
-decreased lung elasticity
-causes SOB, wheezing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

chronic bronchitis

A

-inflammation in the airways(bronchi)
-mucus overproduction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

COPD stimulus

A

-cigarette smoke
-over pollutants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

how often to get spirometry performed?

A

1 x/year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Does COPD have reversibility?

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

COPD spirometry values

A

post bronchodilator FEV1/FVC <0/7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Gold 1: mild

A

FEV1 > 80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Gold 2: moderate

A

50<FEV1< 80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Gold 3: severe

A

3-50% FEV1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

COPD stable, initial treatments

A

-SABA/LABA
-SAMA/LAMA
-or combo products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lonhala Magnair

A

-nebulized Glycopyrrolate
-BID 2-3 min each

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Yupelri

A

-Revefenacin Neb soln
-3 ml
-once daily for 10 min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

LAMA side effects

A

-dry mouth
-bitter taste
-nasopharyngitis
-urinary retention

-worsening of narrow angle glaucoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

LAMA Use in therapy

A

-NOT rescue meds
-do not treat acute COPD symptoms

22
Q

Yupelri drug interactions

A

-OATP1B1
OATP1B3
-rifampin
-cyclosporine

23
Q

Brovana

A

-aformoterol neb soln

24
Q

Perforomost

A

formoterol neb soln

25
Q

LABA side effects

A

-sinus tachycardia
-cardiac rhythm disturbances

26
Q

LABAs place in therapy

A

-monotherapy for patients with mild or moderate COPD
-not rescue medications

27
Q

Considerations for LABAs

A

-other QTc prolong medications
-MAOI

28
Q

LABA/LAMA combo products

29
Q

Anoro ellipta

A

-umeclidium and vilanterol
-interacts with ketoconazole

30
Q

LABA/LAMA place in therapy

A

-step up therapy if patient is still symptomatic

31
Q

SABA

A

-threat acute symptoms

32
Q

ICS

A

-should not be monotherapy
-should be used in tripple therapy
-may even reduce mortality

33
Q

risk of ICS in COPD

A

-higher incidence of pneumonia
-oral candiasis
-hoarse voice

34
Q

Eosinophils

A

-key factor in deciding if patient recieves ICS

35
Q

COPD and asthma

A

-treat like patients with asthma
-always use ICS

36
Q

ICS: Factors strongly favor use

A

-hospitilization for COPD
-> 2 mod exacerbations last year
-eosinophils>300

37
Q

ICS: Factors favor use

A

-1 mod exacerbation
-eosinophil 100-300

38
Q

ICS: Factors againist use

A

-repeated pneumonia events
-eosinophil <100
-hx of mycobacterial infection

39
Q

COPD Assessment Test (CAT)

A

-Higher CAT score is worse symptoms
->30 very high impact

40
Q

Initial: Cat <10 and 0-1 exacebations

A

Bronchodialator

41
Q

Initial: Cat >10 and 0-1 exacebations

A

LABA + LAMA

42
Q

Initial: anyone who has had more than 2 exacerbations or 1 leading to hospitalization

A

-LABA+LAMA
-triple therapy if eosinophils>300

43
Q

Roflumilast

A

-decrease risk of COPD exacebations in SEVERE AND VERY SEVERE COPD

-FEV1<50%
-chronic broncitis
-history of exacerbations

44
Q

Roflumilast side effects

A

-psychiatric events
-weight loss( 2 kg)
-GI upset, diarrhea

45
Q

Roflumilast drug interactions

A

-strong CYP450 inducers
-carbamazapine
=phenytoi
-phenobarbital
-rifampin

46
Q

Roflumilast contraindications

A

-mod to severe liver impairment

47
Q

Azithromycin

A

-for severe COPD AND not a current smoker

48
Q

Azithromycin side effects

A

-prolong QTc
-impaired hearing
-increase bacterial resistance

49
Q

Dupilumab

A

-studied in people eosinophils>300

50
Q

Ensifentrine

A

-nebulizer
-dual PDE3 and PDE4 inhibitor
-bonchodialator
-anti inflammatory

51
Q

step down from ICS therapy

A

-cold turkey
-worse withdrawal with patients that have higher eosinophils

Therapy-556 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions